180 Life Sciences Corporate Media Kit

6 Proposed Business Combination Overview • KBL Merger Corp. IV (“ KBLM ”) has entered into a definitive business combination agreement with 180 Life Sciences Corp. (“ 180 Life Sciences ”) • The transaction is expected to close in early Q4 2020 • It is anticipated that the post-closing company will retain the 180 Life Sciences name and be listed on NASDAQ under the ticker ATNF Transaction Structure • At the time of the business combination, 180 Life Sciences will have 17,500,000 shares issued and outstanding • Each share of 180 Life Sciences will be exchanged for one share of KBLM, valued at $175 million Valuation Illustrative Valuation (in millions, except per share data) Illustrative Proforma Ownership (1) Assumes all convertible debt is converted (2) Based on latest redemption price reported on KBLM 10Q for 06/30/2020 (3) Preferred equity issuable at the closing of the business combination Proforma Shares Outstanding (1) 25.16 Current Redemption Price (2) $10.93 Equity Value $274.95 Debt $1.87 Preferred Equity (3) $3.00 180 Life Sciences Corp. www.180lifesciences.com Q4 2020